AstraZeneca stays silent as reports link it to $9.9 billion Medivation takeover
Anglo-Swedish pharma giant AstraZeneca (LSE: AZN) has declined comment on reports linking it with a $9.9 billion takeover of US biotech firm Medivation (Nasdaq: MDVN).
British newspaper The Sunday Times has cited sources which claim AstraZeneca has held internal talks about a bid for the company, which focuses on cancer treatment drugs. The report states that AstraZeneca has yet to make a formal offer and another British newspaper, The Telegraph, has questioned whether it would be interested.
The Telegraph’s report reasons that AstraZeneca has previously avoided bidding wars so might be unlikely to compete with other rumoured interested parties, such as Switzerland’s Roche (ROG: SIX) and the French company Sanofi (Euronext: SAN), which reportedly had an unsolicited approach snubbed by the Medivation board last week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze